219 related articles for article (PubMed ID: 22767216)
21. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.
Kazimirsky G; Jiang W; Slavin S; Ziv-Av A; Brodie C
Stem Cell Res Ther; 2016 Oct; 7(1):149. PubMed ID: 27724977
[TBL] [Abstract][Full Text] [Related]
22. TRAIL-secreting mesenchymal stem cells promote apoptosis in heat-shock-treated liver cancer cells and inhibit tumor growth in nude mice.
Deng Q; Zhang Z; Feng X; Li T; Liu N; Lai J; Shuai L; Xiong Q; Fu C; Zou H; Wang Y; Li X; Ma K; Bie P
Gene Ther; 2014 Mar; 21(3):317-27. PubMed ID: 24451114
[TBL] [Abstract][Full Text] [Related]
23. Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour.
Fakiruddin KS; Ghazalli N; Lim MN; Zakaria Z; Abdullah S
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060445
[TBL] [Abstract][Full Text] [Related]
24. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
Zhang Y; Zhang B
Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
[TBL] [Abstract][Full Text] [Related]
25. Adipose‑derived mesenchymal stem cell‑facilitated TRAIL expression in melanoma treatment in vitro.
Jing HX; Duan de J; Zhou H; Hu QM; Lei TC
Mol Med Rep; 2016 Jul; 14(1):195-201. PubMed ID: 27177242
[TBL] [Abstract][Full Text] [Related]
26. Mesenchymal stem cells engineered by modified polyethylenimine polymer for targeted cancer gene therapy, in vitro and in vivo.
Salmasi Z; Hashemi M; Mahdipour E; Nourani H; Abnous K; Ramezani M
Biotechnol Prog; 2020 Nov; 36(6):e3025. PubMed ID: 32410328
[TBL] [Abstract][Full Text] [Related]
27. Isolation and characterization of CD105+/CD90+ subpopulation in breast cancer MDA-MB-231 cell line.
Wang X; Liu Y; Zhou K; Zhang G; Wang F; Ren J
Int J Clin Exp Pathol; 2015; 8(5):5105-12. PubMed ID: 26191205
[TBL] [Abstract][Full Text] [Related]
28. Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma.
Yan C; Li S; Li Z; Peng H; Yuan X; Jiang L; Zhang Y; Fan D; Hu X; Yang M; Xiong D
Mol Pharm; 2013 Jan; 10(1):142-51. PubMed ID: 23121392
[TBL] [Abstract][Full Text] [Related]
29. Human mesenchymal stem cells with adenovirus-mediated TRAIL gene transduction have antitumor effects on esophageal cancer cell line Eca-109.
Li L; Li F; Tian H; Yue W; Li S; Chen G
Acta Biochim Biophys Sin (Shanghai); 2014 Jun; 46(6):471-6. PubMed ID: 24739635
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effect of conditioned media derived from murine MSCs and 5-aminolevulinic acid (5-ALA) mediated photodynamic therapy in breast cancer in vitro.
Mohammadpour H; Majidzadeh-A K
Photodiagnosis Photodyn Ther; 2015 Jun; 12(2):238-43. PubMed ID: 25721458
[TBL] [Abstract][Full Text] [Related]
31. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
32. Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.
Vigneswaran N; Baucum DC; Wu J; Lou Y; Bouquot J; Muller S; Zacharias W
BMC Cancer; 2007 Jun; 7():108. PubMed ID: 17592646
[TBL] [Abstract][Full Text] [Related]
33. Engineered human mesenchymal stem cells for neuroblastoma therapeutics.
Nieddu V; Piredda R; Bexell D; Barton J; Anderson J; Sebire N; Kolluri K; Janes SM; Karteris E; Sala A
Oncol Rep; 2019 Jul; 42(1):35-42. PubMed ID: 31115546
[TBL] [Abstract][Full Text] [Related]
34. High expression of TRAIL by osteoblastic differentiated dental pulp stem cells affects myeloma cell viability.
Brunetti G; Di Benedetto A; Posa F; Colaianni G; Faienza MF; Ballini A; Colucci S; Passeri G; Lo Muzio L; Grano M; Mori G
Oncol Rep; 2018 Apr; 39(4):2031-2039. PubMed ID: 29484421
[TBL] [Abstract][Full Text] [Related]
35. Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886.
Kim SM; Woo JS; Jeong CH; Ryu CH; Lim JY; Jeun SS
Cancer Res; 2012 Sep; 72(18):4807-17. PubMed ID: 22962275
[TBL] [Abstract][Full Text] [Related]
36. TRAIL-secreting human mesenchymal stem cells engineered by a non-viral vector and photochemical internalization for pancreatic cancer gene therapy.
Han J; Hwang HS; Na K
Biomaterials; 2018 Nov; 182():259-268. PubMed ID: 30142525
[TBL] [Abstract][Full Text] [Related]
37. Characterization of mesenchymal stem cell subpopulations from human amniotic membrane with dissimilar osteoblastic potential.
Leyva-Leyva M; Barrera L; López-Camarillo C; Arriaga-Pizano L; Orozco-Hoyuela G; Carrillo-Casas EM; Calderón-Pérez J; López-Díaz A; Hernandez-Aguilar F; González-Ramírez R; Kawa S; Chimal-Monroy J; Fuentes-Mera L
Stem Cells Dev; 2013 Apr; 22(8):1275-87. PubMed ID: 23211052
[TBL] [Abstract][Full Text] [Related]
38. Claudin-7 suppresses the cytotoxicity of TRAIL-expressing mesenchymal stem cells in H460 human non-small cell lung cancer cells.
Xia P; Wang W; Bai Y
Apoptosis; 2014 Mar; 19(3):491-505. PubMed ID: 24242915
[TBL] [Abstract][Full Text] [Related]
39. Activated human mesenchymal stem/stromal cells suppress metastatic features of MDA-MB-231 cells by secreting IFN-β.
Yoon N; Park MS; Shigemoto T; Peltier G; Lee RH
Cell Death Dis; 2016 Apr; 7(4):e2191. PubMed ID: 27077807
[TBL] [Abstract][Full Text] [Related]
40. Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.
Yuan Z; Kolluri KK; Sage EK; Gowers KH; Janes SM
Cytotherapy; 2015 Jul; 17(7):885-96. PubMed ID: 25888191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
